Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States) |
| |
| Authors: | Tangrea Joseph A,Albert Paul S,Lanza Elaine,Woodson Karen,Corle Don,Hasson Marsha,Burt Randall,Caan Bette,Paskett Electra,Iber Frank,Kikendall J Walter,Lance Peter,Shike Moshe,Weissfeld Joel,Schatzkin Arthur Polyp Prevention Study Group |
| |
| Affiliation: | (1) Center for Cancer Research, Cancer Prevention Studies Branch, National Cancer Institute, Suite 321, 6006 Executive Blvd, Bethesda, MD 20892-7058, USA;(2) Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA;(3) Cancer Prevention Studies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA;(4) Biometry Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA;(5) Westat, Rockville, MD, USA;(6) University of Utah, Salt Lake City, UT, USA;(7) Kaiser Foundation Research Institute, Oakland, CA, USA;(8) Wake Forest University School of Medicine, Winston-Salem, NC, USA;(9) Edward Hines, Jr, Hospital, Veterans Affairs Medical Center, Hines, IL, USA;(10) Walter Reed Army Medical Center, Washington, DC, USA;(11) School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY, USA;(12) Memorial Sloan-Kettering Cancer Center, New York, NY, USA;(13) University of Pittsburgh, Pittsburgh, PA, USA;(14) Nutritional Epidemiology Branch, Division of Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA |
| |
| Abstract: | Objective: To prospectively examine the association between non-steroidal anti-inflammatory drugs (NSAIDs) use (including dose and dosage schedule) and the recurrence of colorectal adenomas among individuals who were diagnosed with an adenoma at entry into a clinical trial. Methods: For this analysis, participants who completed the full follow-up (n = 1905) for the Polyp Prevention Trial (PPT) were evaluated. Information on current use and dose of NSAIDs and other drugs was obtained at baseline and at each subsequent study visit over the duration of the trial. The study endpoint was the recurrence of colorectal adenomas in the 3 years between the 1-year trial colonoscopy (T1) and the end of the trial colonoscopy (T4). Results: There was a significant reduction in overall adenoma recurrence among NSAIDs users (odds ratio [OR] = 0.77; 95% confidence interval [CI]: 0.63–0.95), with the greatest effect seen in advanced polyps (OR = 0.51; CI: 0.33–0.79). Among aspirin users, we observed a significant dose response for overall adenoma recurrence, with a 40% reduction in the OR association (OR = 0.56; 95% CI: 0.31–0.99) among those taking more than 325 mg per day. Conclusion: This prospective study provides further evidence that NSAIDs may play an important role in the chemoprevention of recurrent colorectal adenomas, even those with advanced features. |
| |
| Keywords: | adenomas non-steroidal anti-inflammatory drugs prospective risk |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
